BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tagitanlimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tagitanlimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07108816-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07108816)
DESCRIPTION:Tagitanlimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Single-center\, Phase II Clinical Trial Evaluating the Efficacy of Sacituz
 umab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy f
 or PD-L1-positive\, Resectable Stage II to IIIB Non-small Cell Lung Cancer
  (NSCLC)\nEstimated primary completion: 30 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07108816
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492914-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07492914)
DESCRIPTION:Tagitanlimab\, phase 2.\nStudy: Neoadjuvant Sacituzumab Govitec
 an Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tagitanlimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07492914
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179783-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07179783)
DESCRIPTION:Tagitanlimab\, phase 2.\nStudy: Sacituzumab Tirumotecan in Comb
 ination With Tagitanlimab in the Treatment of Aggressive Variant Prostate 
 Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)\nEstimated primary
  completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tagitanlimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07179783
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258108-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07258108)
DESCRIPTION:Tagitanlimab\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Sac-TMT Plus KL-A167 in PD-L1+\, HR+/HER2- Metastatic Breast Cancer 
 After CDK4/6 Inhibitors\nEstimated primary completion: 30 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07258108
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05294172-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagitanlimab: Phase 3 readout est. (NCT05294172)
DESCRIPTION:Tagitanlimab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: KL-A
 167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined 
 With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic
  Nasopharyngeal Carcinoma\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05294172
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109284-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07109284)
DESCRIPTION:Tagitanlimab\, phase 2.\nStudy: SKB264 Combined With KL-A167 Ne
 oadjuvant Therapy for Early-stage\, High-risk ER+/HER2- Breast Cancer\nEst
 imated primary completion: January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tagitanlimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07109284
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371208-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07371208)
DESCRIPTION:Tagitanlimab\, phase 2.\nStudy: Multicenter\, Phase II Clinical
  Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 fo
 r Neoadjuvant Treatment of Triple-Negative Breast Cancer\nEstimated primar
 y completion: August 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tagitanlimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07371208
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701681-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07701681)
DESCRIPTION:Tagitanlimab\, phase 2.\nStudy: Sacituzumab Tirumotecan (Sac-TM
 T/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metast
 atic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junct
 ion Adenocarcinoma\nEstimated primary completion: 1 September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07701681
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07738757-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07738757)
DESCRIPTION:Tagitanlimab\, phase 2.\nStudy: SKB264 Plus KL-A167 in MSI-H/dM
 MR Advanced Gynecological Malignancies\nEstimated primary completion: 1 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tagitan
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07738757
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296809-2581@assetmemo.bio
DTSTAMP:20261121T005647Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07296809)
DESCRIPTION:Tagitanlimab\, phase 2.\nStudy: SKB500 Combinations in Patients
  With Small Cell Lung Cancer\nEstimated primary completion: 31 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tagitanlimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07296809
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
